rts logo

Positives for Xilio Therapeutics Inc (XLO) as stock gains in recent trading

MQ Stock

Xilio Therapeutics Inc (NASDAQ: XLO) is 178.18% higher on its value in year-to-date trading and has touched a low of $0.49 and a high of $3.67 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The XLO stock was last observed hovering at around $1.08 in the last trading session, with the day’s gains setting it 0.45%.

Currently trading at $1.53, the stock is 108.23% and 127.31% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 21.25 million and changing 41.67% at the moment leaves the stock -8.48% off its SMA200. XLO registered -49.17% loss for a year compared to 6-month loss of -29.17%. The firm has a 200-day simple moving average (SMA200) of $0.19.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

The stock witnessed a 115.80% gain in the last 1 month and extending the period to 3 months gives it a 168.42%, and is 116.25% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 31.93% over the week and 18.88% over the month.

Distance from 52-week low is 212.24% and -58.31% from its 52-week high. The company has generated returns on investments over the last 12 months (-133.33%).

Xilio Therapeutics Inc quarterly earnings per share for the current quarter are estimated at -$0.64.The EPS is expected to grow by 30.13% this year.

Xilio Therapeutics Inc (XLO) Top Institutional Holders

39 institutions hold shares in Xilio Therapeutics Inc (XLO), with institutional investors hold 63.87% of the company’s shares. The shares outstanding are 27.54M, and float is at 13.85M with Short Float at 0.42%. Institutions hold 56.53% of the Float.

The top institutional shareholder in the company is Bain Capital Life Sciences Investors, LLC with over 2.81 million shares valued at $7.35 million. The investor’s holdings represent 10.19% of the XLO Shares outstanding. As of Jun 29, 2023, the second largest holder is Atlas Venture Life Science Advisors, LLC with 2.76 million shares valued at $7.23 million to account for 10.02% of the shares outstanding. The other top investors are Octagon Capital Advisors LP which holds 2.42 million shares representing 8.81% and valued at over $6.35 million, while FMR, LLC holds 6.93% of the shares totaling 1.91 million with a market value of $5.0 million.

Xilio Therapeutics Inc (XLO) Insider Activity

The most recent transaction is an insider sale by Atlas Venture Fund XI, L.P.,the company’s10% Owner. SEC filings show that Atlas Venture Fund XI, L.P. sold 733 shares of the company’s common stock on Feb 08 ’24 at a price of $0.64 per share for a total of $469.0. Following the sale, the insider now owns 2.02 million shares.

Xilio Therapeutics Inc disclosed in a document filed with the SEC on Feb 08 ’24 that Atlas Venture Fund XI, L.P. (10% Owner) sold a total of 267 shares of the company’s common stock. The trade occurred on Feb 08 ’24 and was made at $0.64 per share for $171.0. Following the transaction, the insider now directly holds 0.73 million shares of the XLO stock.

Still, SEC filings show that on Jan 12 ’24, Atlas Venture Fund XI, L.P. (10% Owner) disposed off 1,540 shares at an average price of $0.83 for $1278.0. The insider now directly holds 2,020,296 shares of Xilio Therapeutics Inc (XLO).

Related Posts